Pasireotide Diaspartate Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 0.3 mg/mL, 0.6 mg/mL, 1.2 mg/mL, 10 mg, 20 mg, 30 mg

Reference Brands: Signifor (USA/EU)

Category: Orphan Drugs

Pasireotide Diaspartate is available in Injection and strengths such as 0.3 mg/mL, 0.6 mg/mL, 1.2 mg/mL, 10 mg, 20 mg, 30 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Pasireotide Diaspartate is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Pasireotide Diaspartate can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Pasireotide is an orphan drug used for the treatment of Cushing’s disease in patients who are not candidates for pituitary surgery or have persistent or recurrent disease following surgery. Marketed under the brand name Signifor, Pasireotide was developed by Novartis and has received approval in the United States and European Union for this rare endocrine disorder.

It is a synthetic somatostatin analogue with a uniquely high affinity for somatostatin receptor subtype 5, approximately 40 times greater than other somatostatin analogues. By selectively binding to this receptor, Pasireotide effectively inhibits excess adrenocorticotropic hormone (ACTH) secretion, leading to reduced cortisol production and helping restore hormonal balance in patients with Cushing’s disease.

Pasireotide is available in both short-acting subcutaneous formulations and long-acting intramuscular depot injections, offering flexibility in treatment schedules ranging from daily to monthly dosing. Due to its targeted mechanism of action, patients require monitoring for potential effects on glucose metabolism, liver function, and gallbladder health. As an orphan drug, Pasireotide provides a specialized therapeutic option for managing a rare and challenging endocrine condition.